Glaxosmithkline announced collaboration with Chroma Therapeutics to develop
macrophage-targeted compounds. Chroma has the potential to receive in excess of $1 billion in total milestone and option payments from GSK. Chroma will receive a significant upfront cash payment and GSK will invest in Chroma's Series D equity financing.